ATEZOLIZUMAB

atezolizumab 840 mg/14 mL injection, 14 mL vial

ATEZOLIZUMAB (13170E)

atezolizumab 840 mg/14 mL injection, 14 mL vial
13170E
Body System:
Manner of administration:Injection
Private
Chemotherapy Items for Private Hospital use
Authority Required (STREAMLINED)

Restriction  13451

Indication: Resected early stage (Stage II to IIIA) non-small cell lung cancer (NSCLC)
Treatment phase: 1,680 mg administered once every 4 weeks, or 840 mg every 2 weeks
Quantities & Cost
Max amount # of repeats DPMA Max safety net General Patient Charge
Max amount: 1680 mg # of repeats: 5 DPMA: $9,715.44 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Tecentriq
(atezolizumab 840 mg/14 mL injection, 14 mL vial)